Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Lung Cancer

    An Introduction to Lung Cancer

    In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lung Cancer Content

    Lung Cancer
    Developed by Touch
    Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
    Watch Time: 5 mins

    Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]

    Lung Cancer
    Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer
    Linda Martin

    touchREVIEWS in Oncology & Haematology. 2023;19(1):2-3 DOI: https://doi.org/10.17925/OHR.2023.19.1.2

    Accurately detecting lung tumours and their margins is important for disease outcomes.1,2 However, detection is challenging due to the use of minimally invasive surgery and current localization techniques, such as computed tomography (CT)-guided and endobronchial interventions, which add significantly to procedure time and risk of complications.3 Intraoperative imaging using a targeted agent to optically fluoresce cancerous cells may address these problems, in addition to locating […]

    Lung Cancer, Immunotherapy
    Watch Time: 48 mins
    touchMDT
    Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations
    CE/CME ACCREDITED Prof. Raffaele Califano, Prof. Lisa Holle, Prof. Albrecht Stenzinger and Mr Josh Colow Translations available:

    Leading specialists and a patient advocate discuss novel immunotherapies for non-driver mutation metastatic non-small cell lung cancer (NSCLC).

    Learning objectives
    Learning Objectives
    • Outline the determinants of response and resistance to immune checkpoint blockade in patients with non-driver mutation metastatic NSCLC
    • Discuss the mechanisms of action and latest data for novel immunotherapy regimens in the management of non-driver mutation metastatic NSCLC
    • Appraise strategies for involving patients with non-driver mutation metastatic NSCLC in their healthcare for optimal outcomes
    Lung Cancer
    Watch Time: 31 mins
    touchPANEL DISCUSSION
    Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
    Prof. Jarushka Naidoo, Dr Rebecca Heist, Dr Antonio Passaro Translations available:

    Experts in the management of lung cancer discuss emerging antibody-drug conjugates for the treatment of patients with non-small cell lung cancer (NSCLC)

    Learning objectives
    Learning Objectives
    • Outline the rationale for and mechanisms of action for antibody drug conjugates (ADCs) under investigation in NSCLC, and implications for patient selection
    • Evaluate the latest clinical trial data for ADCs in patients with advanced or metastatic NSCLC
    • Discuss incidence rates and severity of adverse events (AEs) associated with ADCs in metastatic NSCLC and potential role for therapeutic dose optimization strategies in AE management
    Lung Cancer
    Watch Time: 38 mins
    touchMDT
    Continuing the momentum in SCLC: Exploring second-line and novel therapy options
    CE/CME ACCREDITED Dr Barbara Melosky, Dr Sonia Amin Thomas, Dr Christine Argento, Dr Victoria Sherry

    MDT specialists discuss the current and emerging second-line treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC)

    Learning objectives
    Learning Objectives
    • Describe the current and emerging second-line treatment options for patients with SCLC
    • Identify patient- and disease-related factors that affect treatment decisions for patients with SCLC in the second-line setting
    • Describe strategies to manage adverse events for patients with SCLC in the second-line treatment setting
    Lung Cancer
    Developed by Touch
    Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
    Watch Time: 4 mins

    First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]

    Lung Cancer
    Developed by Touch
    Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
    Watch Time: 6 mins

    The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]

    Lung Cancer, Immunotherapy
    Watch Time: 35 mins
    touchPANEL DISCUSSION
    Exploring the latest advances in first-line treatment of ES-SCLC: Translating the data to clinical practice
    CE/CME ACCREDITED Dr Marina Garassino, Dr Luis Paz-Ares, Dr Martin J Edelman Translations available:

    Watch leading lung cancer experts share their insights on the latest advancements in first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

    Learning objectives
    Learning Objectives
    • Recall the latest data on the efficacy of ICI-combination approaches for ES-SCLC in the first-line setting
    • Describe the latest safety data for ICI-combination approaches for patients with ES-SCLC
    • Discuss ongoing ICI clinical trial data and preclinical trials in ES-SCLC
    Lung Cancer, Colorectal Cancer
    Watch Time: 30 mins
    touchTALKS
    Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
    Prof. Tony Mok Translations available:

    Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.

    Learning objectives
    Learning Objectives
    • Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
    • Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
    • Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72